On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE:NVS) Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary ...

Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to ...

Full FDA Approval of Travere’s Kidney Drug Stiffens Competition With Novartis, Calliditas The FDA decision for Travere Therapeutics’ Filspari also expands its addressable patient population.

The U.S. Food and Drug Administration has approved the use of Novartis' drug to reduce excess protein in the urine of patients with a type of kidney disease, the health regulator's website showed ...

Novartis said it received accelerated approval from the U.S. Food and Drug Administration for a treatment to bring down elevated levels of protein in the urine of adults who have a rare kidney ...

Novartis' Fabhalta (iptacopan) receives FDA accelerated approval as a first-in-class complement inhibitor for IgA nephropathy, reducing proteinuria in adults at risk of rapid disease progression ...

Novartis wins FDA approval for the label expansion of Fabhalta for a third indication - treatment of adults with C3 glomerulopathy.

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory reviews continue.

On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE:NVS) Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary ...